Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial

10.1016/j.bbmt.2019.09.032 ◽

2020 ◽

Vol 26 (2) ◽

pp. 316-322

Author(s):

Jacopo Peccatori ◽

Sara Mastaglio ◽

Fabio Giglio ◽

Raffaella Greco ◽

Roberto Crocchiolo ◽

...

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

10.1016/j.bbmt.2013.07.008 ◽

2013 ◽

Vol 19 (10) ◽

pp. 1453-1458 ◽

Cited By ~ 14

Author(s):

Qaiser Bashir ◽

Hassan Khan ◽

Peter F. Thall ◽

Ping Liu ◽

Nina Shah ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Hematopoietic Stem ◽

Randomized Phase Ii

Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial

10.1016/j.bbmt.2018.07.013 ◽

2018 ◽

Vol 24 (11) ◽

pp. 2310-2315 ◽

Cited By ~ 1

Author(s):

Chien-Ting Lin ◽

Po-Ren Hsueh ◽

Shang-Ju Wu ◽

Ming Yao ◽

Bor-Sheng Ko ◽

...

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Cytomegalovirus Infection ◽

Phase Ii Trial ◽

Infection Prophylaxis ◽

Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan

American Journal of Hematology ◽

10.1002/ajh.20977 ◽

2007 ◽

Vol 82 (10) ◽

pp. 873-880 ◽

Cited By ~ 12

Author(s):

Akiko M. Saito ◽

Masahiro Kami ◽

Shin-Ichiro Mori ◽

Yoshinobu Kanda ◽

Ritsuro Suzuki ◽

...

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Hematopoietic Stem ◽

Prospective Phase ◽

Kinetics Of

Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft-vs.-Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)

10.1016/j.bbmt.2010.12.417 ◽

2011 ◽

Vol 17 (2) ◽

pp. S291

Author(s):

Z. Al-Kadhimi ◽

Z. Gul ◽

R. Rodriguez ◽

W. Chen ◽

A. Mitchell ◽

...

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Hematopoietic Stem ◽

Graft Vs Host Disease ◽

Acute Graft

Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

10.1016/j.bbmt.2013.12.367 ◽

2014 ◽

Vol 20 (2) ◽

pp. S217-S218

Author(s):

Yi-Bin Chen ◽

Shuli Li ◽

Candice Del Rio ◽

Erin Coughlin ◽

Karen K. Ballen ◽

...

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Hematopoietic Stem ◽

Reduced Intensity

Signal mass change as a marker of brain tissue loss in multiple sclerosis patients following immunoablative therapy and autologous hematopoietic stem cell transplantation

10.26226/morressier.5b719e465aff74008ae4c9f9 ◽

2018 ◽

Author(s):

Hyunwoo Lee ◽

Robert A. Brown ◽

Douglas L. Arnold

Keyword(s):

Multiple Sclerosis ◽

Stem Cell ◽

Brain Tissue ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Tissue Loss ◽

Hematopoietic Stem ◽

Multiple Sclerosis Patients

Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis

Experimental Hematology ◽

10.1016/j.exphem.2012.07.003 ◽

2012 ◽

Vol 40 (11) ◽

pp. 892-898 ◽

Cited By ~ 33

Author(s):

Jury L. Shevchenko ◽

Alexey N. Kuznetsov ◽

Tatyana I. Ionova ◽

Vladimir Y. Melnichenko ◽

Denis A. Fedorenko ◽

...

Keyword(s):

Multiple Sclerosis ◽

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Reduced Intensity Conditioning ◽

Hematopoietic Stem ◽

Reduced Intensity

Modifications to the “Classical” Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Less Toxic Approach is Feasible and Improves the Neurological Condition. A Mexican Perspective

10.1016/j.bbmt.2017.12.067 ◽

2018 ◽

Vol 24 (3) ◽

pp. S125-S126 ◽

Cited By ~ 1

Author(s):

Guillermo Jose Ruiz-Argüelles ◽

Juan Carlos Olivares-Gazca ◽

Iván Murrieta-Álvarez ◽

David Blumenkron-Marroquin ◽

Elías González-López ◽

...

Keyword(s):

Multiple Sclerosis ◽

Stem Cell ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Hematopoietic Stem ◽

Neurological Condition ◽

Toxic Approach

A Case of Systemic Sclerosis Developed after Autologous Hematopoietic Stem Cell Transplantation in the Patient with Multiple Sclerosis

The Korean Journal of Hematology ◽

10.5045/kjh.2005.40.2.106 ◽

2005 ◽

Vol 40 (2) ◽

pp. 106

Author(s):

Woo Sin Kim ◽

Chang-Ki Min ◽

Dong Won Yang ◽

Yu Kyung Park ◽

Son Ook Choi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Stem Cell ◽

Systemic Sclerosis ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽